A study that utilized ambroxol, which is used as a treatment for lysosomal storage disease, found that it induces Neu1 expression, leading to IR activation and improves insulin signaling and glucose metabolism in HepG2 cell line, making it a promising candidate to reverse insulin resistance in Type 2 diabetes mellitus (T2DM) (58). Here, NEU1 is linked to type 2 diabetes mellitus.